ClinicalTrials.Veeva
Menu

Find clinical trials for Chronic Lymphocytic Leukemia in Sevilla, AN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Chronic Lymphocytic Leukemia
Leukemia
Lymphoma
Lymphoid Leukemia
Mantle-Cell Lymphoma
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma

Chronic Lymphocytic Leukemia trials near Sevilla, AN, ESP:

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia...

Begins enrollment in 2 months
Lymphoma, Small Lymphocytic
Chronic Lymphocytic Leukemia
Drug: Pirtobrutinib
Drug: Idelalisib

Phase 4

Lilly
Lilly

Seville, Spain and 49 other locations

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Pirtobrutinib
Drug: BGB-16673

Phase 3

BeOne Medicines

Seville, Spain and 38 other locations

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)

The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL wh...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Pirtobrutinib
Drug: Bendamustine

Phase 3

Loxo Oncology
Loxo Oncology

Sevilla, Spain and 107 other locations

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314)

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; par...

Enrolling
Leukemia, B-cell
Small Lymphocytic Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

Phase 3

Loxo Oncology
Loxo Oncology

Seville, Spain and 147 other locations

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic ...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Pirtobrutinib

Phase 2

Loxo Oncology
Loxo Oncology

Seville, Spain and 135 other locations

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Rituximab
Drug: Sonrotoclax

Phase 3

BeiGene
BeiGene

Seville, Spain and 89 other locations

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1)

Epcoritamab will be tested either inRelapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as:* Monotherapy, or* Com...

Enrolling
Small Lymphocytic Lymphoma
Treatment-naïve High Risk Chronic Lymphocytic Leukemia
Drug: Lenalidomide
Drug: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

Phase 1, Phase 2

Genmab
Genmab

Seville, Spain and 86 other locations

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...

Enrolling
Chronic Lymphocytic Leukemia
Drug: Acalabrutinib
Drug: Obinutuzumab

Phase 3

AbbVie
AbbVie

Seville, Spain and 69 other locations

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Rituximab

Phase 3

Loxo Oncology
Loxo Oncology

Seville, Spain and 179 other locations

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW)

The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...

Active, not recruiting
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: Obinutuzumab
Drug: Venetoclax

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Seville, Spain and 87 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems